How Much Does Zepbound Cost? (2026)

Zepbound List Price Breakdown

Zepbound is manufactured by Eli Lilly and FDA-approved for chronic weight management in adults with a BMI of 30+ (obesity) or 27+ (overweight) with at least one weight-related condition. It contains tirzepatide, which activates both GLP-1 and GIP receptors — a dual mechanism that clinical trials show produces greater weight loss than semaglutide alone.

The wholesale acquisition cost (WAC) varies by dose:

• 2.5 mg (starting dose, weeks 1-4): $1,060/month
• 5 mg (maintenance): $1,060/month
• 7.5 mg (escalated): $1,060/month
• 10 mg (escalated): $1,060/month
• 12.5 mg (escalated): $1,060/month
• 15 mg (maximum dose): $1,060/month

Like Ozempic, all doses carry the same list price. At retail pharmacy without any discounts, you will pay approximately $1,060/month. However, Eli Lilly has taken a dramatically different approach to pricing than Novo Nordisk, offering aggressive self-pay programs that make Zepbound one of the most affordable brand-name GLP-1 options.

Zepbound Cost With Insurance

Insurance coverage for Zepbound has improved significantly since its November 2023 launch, though coverage remains inconsistent across plans:

Pro tip: Some insurers cover Mounjaro (same drug, tirzepatide, diabetes indication) but not Zepbound. If you have type 2 diabetes, ask your doctor about Mounjaro — it may have better insurance coverage. See Mounjaro pricing.

Savings Cards and Discount Programs

Eli Lilly offers multiple programs to reduce the cost of Zepbound:

Medicare Coverage: The GLP-1 Bridge Since July 2026

Medicare covers Zepbound for weight management under the GLP-1 Bridge, which launched July 1, 2026, at $50/month for eligible beneficiaries. Zepbound is one of the medications named in the programme, the first time Medicare has covered a GLP-1 for weight management.

• Covered for weight management under Medicare Part D at $50/month
• Prior authorization: BMI documentation and a record of lifestyle modification
• All doses from 2.5 mg to 15 mg are covered; the Lilly savings card cannot be combined with Medicare

For a beneficiary who was paying $299–$449/month through LillyDirect, the Bridge cuts the cost by roughly 83–89%. Read our full Medicare GLP-1 coverage guide.

Zepbound vs Ozempic and Wegovy: Cost Comparison

Zepbound's pricing strategy is fundamentally different from Novo Nordisk's approach with Ozempic and Wegovy. Here is how they compare:

• Ozempic ($998/month list): No manufacturer self-pay program comparable to LillyDirect; the cash route to the same molecule is compounded semaglutide from $69/month. FDA-approved for diabetes only. See Ozempic pricing.
• Wegovy ($1,349/month list): Same semaglutide as Ozempic but for weight loss. Oral Wegovy available at $149/month for the starting dose, but Zepbound shows greater weight loss in clinical trials. See Wegovy pricing.
• Mounjaro ($1,023/month list): Same tirzepatide as Zepbound but for diabetes. If you have type 2 diabetes, Mounjaro may have better insurance coverage. See Mounjaro pricing.

Bottom line: For self-pay patients seeking weight loss, Zepbound at $299–$449/month through LillyDirect offers the best combination of trial results and price among FDA-approved injectables; the Wegovy pen self-pay is $349, and the two approved pills cost $149 but lose less.

Zepbound Safety and Cost Over a Year

A year of Zepbound costs $12,720 at list, $3,588–$5,388 through LillyDirect vials, $300 on a covered commercial plan with the savings card, $600 on the Medicare Bridge, or about $1,428 for the cheapest compounded tirzepatide we track. Most patients titrate to a maintenance dose within four to five months, so the maintenance-dose vial price, not the starting-dose price, decides the annual bill.

On safety, Zepbound is FDA-approved with the GLP-1 class boxed warning about thyroid C-cell tumours seen in rodent studies; it should not be used with a personal or family history of medullary thyroid carcinoma or MEN 2. The common side effects are gastrointestinal, nausea, diarrhea, constipation and decreased appetite, worst during dose escalation. Compounded tirzepatide carries the same molecule without an FDA-approved finished product, so the pharmacy and prescriber, not the FDA, stand behind each vial; every compounded provider we list is vetted for licensed pharmacies and licensed prescribers, and FDA warning letters are flagged on the relevant review pages.